The cellular and molecular mechanisms for neutropenia in Barth syndrome

European Journal of Haematology

Volumn 88, Issue 3, 2012, Pages 195-209

  Makaryan, Vahagn ^a   Kulik, Willem ^b   Vaz, Frederic M ^b   Allen, Christopher ^c   Dror, Yigal ^c   Dale, David C ^a   Aprikyan, Andrew A ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Foundation for Research Experiential Educational Developmental Operational Management   (United States)

Author keywords

Apoptosis; Mitochondria; Neutropenia; Tafazzin

Indexed keywords

ACYLTRANSFERASE; ANNEXIN; CARDIOLIPIN; CASPASE 3; CYTOCHROME C; SHORT HAIRPIN RNA; TAFAZZIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BARTH SYNDROME; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR PATHOLOGY; MYELOID PROGENITOR CELL; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BARTH SYNDROME; CARDIOLIPINS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE SILENCING; HL-60 CELLS; HUMANS; JURKAT CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MYELOID PROGENITOR CELLS; NEUTROPENIA; PRECURSOR CELLS, T-LYMPHOID; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; U937 CELLS;

EID: 84856964223     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01725.x     Document Type: Article

References (54)

1. Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen IE, Van't Veer-Korthof ET, Van der Harten JJ, Sobotka-Plojar MA. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci 1983;62:327-55.
2. Geha J, Notarangelo LD, Casanova J-L, et al. The international union of immunological societies (IUIS) primary immunodeficiency diseases (PID) classification committee. J Allergy Clin Immunol 2007;120:776-94.
3. Gedeon AK, Wilson MJ, Colley AC, Sillence DO, Mulley JC. X-linked fatal infantile cardiomyopathy maps to Xq28 and is possibly allelic to Barth syndrome. J Med Genet 1995;32:383-8.
4. Kelley RI, Cheatham JP, Clark BJ, Nigro MA, Powell BR, Sherwood GW, Sladky JT, Swisher WP. X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria. J Pediatr 1991;119:738-47.
5. Bolhuis PA, Hensels GW, Hulsebos TJ, Baas F, Barth PG. Mapping of the locus for X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. Am J Hum Genet 1991;48:481-5.
6. Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet 1996;12:385-9.
7. Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz FM, Wanders RJ. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet A 2004;126:349-54.
8. Neuwald AF. Barth syndrome may be due to an acyltransferase deficiency. Curr Biol 1997;7:R465-6.
9. Ades LC, Gedeon AK, Wilson MJ, Latham M, Partington MW, Mulley JC, Nelson J, Lui K, Sillence DO. Barth syndrome: clinical features and confirmation of gene localisation to distal Xq28. Am J Med Genet 1993;45:327-34.
10. Christodoulou J, McInnes RR, Jay V, Wilson G, Becker LE, Lehotay DC, Platt BA, Bridge PJ, Robinson BH, Clarke JT. Barth syndrome: clinical observations and genetic linkage studies. Am J Med Genet 1994;50:255-64.
11. Johnston J, Kelley RI, Feigenbaum A, Cox GF, Iyer GS, Funanage VL, Proujansky R. Mutation characterization and genotype-phenotype correlation in Barth syndrome. Am J Hum Genet 1997;61:1053-8.
12. Bachou T, Giannakopoulos A, Trapali C, Vazeou A, Kattamis A. A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. Blood Cells Mol Dis 2009;42:262-4.
13. Chen R, Tsuji T, Ichida F, et al. Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. Mol Genet Metab 2002;77:319-25.
14. Vreken P, Valianpour F, Nijtmans LG, Grivell LA, Plecko B, Wanders RJ, Barth PG. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun 2000;279:378-82.
15. D'Adamo P, Fassone L, Gedeon A, et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997;61:862-7.
16. Bleyl SB, Mumford BR, Thompson V, Carey JC, Pysher TJ, Chin TK, Ward K. Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet 1997;61:868-78.
17. Chang B, Momoi N, Shan L, et al. Gonadal mosaicism of a TAZ (G4.5) mutation in a Japanese family with Barth syndrome and left ventricular noncompaction. Mol Genet Metab 2010;100:198-203.
18. Valianpour F, Mitsakos V, Schlemmer D, et al. Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis. J Lipid Res 2005;46:1182-95.
19. Schlame M, Rua D, Greenberg ML. The biosynthesis and functional role of cardiolipin. Prog Lipid Res 2000;39:257-88.
20. Valianpour F, Wanders RJ, Overmars H, Vreken P, Van Gennip AH, Baas F, Plecko B, Santer R, Becker K, Barth PG. Cardiolipin deficiency in X-linked cardioskeletal myopathy and neutropenia (Barth Syndrome, MIM 302060): a study in cultured skin fibroblasts. J Pediatr 2002;141:729-33.
21. Xu Y, Condell M, Plesken H, Edelman-Novemsky I, Ma J, Ren M, Schlame M. A Drosophila model of Barth syndrome. Proc Natl Acad Sci U S A 2006;103:11584-8.
22. Khuchua Z, Yue Z, Batts L, Strauss AW. A zebrafish model of human Barth syndrome reveals the essential role of tafazzin in cardiac development and function. Circ Res 2006;21:99.
23. Acehan D, Xu Y, Stokes DL, Schlame M. Comparison of lymphoblast mitochondria from normal subjects and patients with Barth syndrome using electron microscopic tomography. Lab Invest 2007;87:40-8.
24. Kuijpers TW, Maianski NA, Tool AT, et al. Neutrophils in Barth syndrome (BTHS) avidly bind annexin-V in the absence of apoptosis. Blood 2004;103:3915-23.
25. He Q. Tafazzin knockdown causes hypertrophy of neonatal ventricular myocytes. Am J Physiol Heart Circ Physiol 2010;299:H210-6.
26. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977;270:347-9.
27. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
28. Ozgen U, Savasan S, Buck S, Ravindranath Y. Comparison of DiOC(6)(3) uptake and annexin V labeling for quantification of apoptosis in leukemia cells and non-malignant T lymphocytes from children. Cytometry 2000;42:74-8.
29. Aprikyan AA, Kutyavin T, Stein S, Aprikian P, Rodger E, Liles WC, Boxer LA, Dale DC. Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. Exp Hematol 2003;31:372-81.
30. Houtkooper RH, Rodenburg RJ, Thiels C, et al. Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. Anal Biochem 2009;387:230-7.
31. 3 involves cell cycle arrest in G1 that is preceded by a transient proliferative Burst and an increase in cyclin expression. Blood 1999;93:2721-9.
32. Schlame M, Towbin JA, Heerdt PM, Jehle R, DiMauro S, Blanck TJ. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann Neurol 2002;51:634-7.
33. Malhotra A, Edelman-Novemsky I, Xu Y, Plesken H, Ma J, Schlame M, Ren M. Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome. Proc Natl Acad Sci U S A 2009;106:2337-41.
34. Saini-Chohan HK, Holmes MG, Chicco AJ, Taylor WA, Moore RL, McCune SA, Hickson-Bick DL, Hatch GM, Sparagna GC. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J Lipid Res 2009;50:1600-8.
35. Kulik W, van Lenthe H, Stet FS, Houtkooper RH, Kemp H, Stone JE, Steward CG, Wanders RJ, Vaz FM. Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome. Clin Chem 2008;54:371-8.
36. Gottlieb E, Armour SM, Harris MH, Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ 2003;10:709-17.
37. Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Cytochrome c release form mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A 2002;99:1259-63.
38. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssière JL, Petit PX, Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995;181:1661-72.
39. Aprikyan AA, Liles WC, Rodger E, Jonas M, Chi EY, Dale DC. Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. Blood 2001;97:147-53.
40. Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, Rommens JM. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 2003;33:97-101.
41. Horwitz M, Benson KF, Person RE, Aprikyan AG, Dale DC. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic neutropenia. Nat Genet 1999;23:433-6.
42. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000;96:2317-22.
43. Klein C, Grudzien M, Appaswamy G, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007;39:86-92.
44. Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001;27:313-7.
45. Gonzalvez F, Schug ZT, Houtkooper RH, MacKenzie ED, Brooks DG, Wanders RJ, Petit PX, Vaz FM, Gottlieb E. Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. J Cell Biol 2008;183:681-96.
46. Houtkooper RH, Turkenburg M, Poll-The BT, Karall D, Pérez-Cerdá C, Morrone A, Malvagia S, Wanders RJ, Kulik W, Vaz FM. The enigmatic role of tafazzin in cardiolipin metabolism. Biochim Biophys Acta 2009;1788:2003-14.
47. Acehan D, Vaz F, Houtkooper RH, et al. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome. J Biol Chem 2011;286:899-908.
48. Soustek MS, Falk D, Mah C, Toth M, Schlame M, Lewin A, Byrne B. Characterization of a transgenic shRNA induced murine model of Tafazzin deficiency. Hum Gene Ther 2011;22:865-71.
49. van Raam BJ, Sluiter W, de Wit E, Roos D, Verhoeven AJ, Kuijpers TW. Mitochondrial membrane potential in human neutrophils is maintained by complex III activity in the absence of supercomplex organisation. PLoS One 2008;3:E2013.
50. Fossati G, Moulding DA, Spiller DG, Moots RJ, White MR, Edwards SW. The mitochondrial network of human neutrophils: role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J Immunol 2003;170:1964-72.
51. Kohlhaas M, Liu T, Knopp A, Zeller T, Ong MF, Böhm M, O'Rourke B, Maack C. Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation 2010;121:1606-13.
52. Khryapenkova TG, Plotnikov EY, Korotetskaya MV, Sukhikh GT, Zorov DB. Heterogeneity of mitochondrial potential as a marker for isolation of pure cardiomyoblast population. Bull Exp Biol Med 2008;146:506-11.
53. Baskin-Bey ES, Washburn K, Feng S, et al. Clinical trial of the Pan-Caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007;7:218-25.
54. Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JC, Hoffman HM. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory Syndrome patients. J Immunol 2005;175:2630-4.